Biologic activity and quantification of messenger RNA coding for human chorionic somatomammotropin in normal and intrauterine growth--retarded pregnancies.
Total ribonucleic acid (RNA) from human placentas obtained from normal and intrauterine growth--retarded (IUGR) pregnancies was translated in a reticulocyte cell--free system. Synthesis of human chorionic somatomammotropin (hCS) was estimated as a ratio of specific immunoprecipitated protein over total newly synthesized proteins. There is no significant difference between in vitro hCS synthesis directed by placental RNA from normal and IUGR pregnancies. Measurements of messenger RNA sequences coding for hCS, with a hCS complementary DNA probe, indicated that the hCS messenger RNA (mRNA) concentrations were similar for both groups. Low plasma hCS levels in pregnancies associated with growth-retarded fetuses can be explained by their significantly lower placental weights which correlate with their total RNA content. The total capacity of in vitro hCS production per placenta is significantly lower in this type of abnormal pregnancy. There is a good parallelism between the amount of hCS mRNA, its biologic activity tested in a cell-free system, and the secretion of hCS in the maternal circulation. These data suggest that there is no basic intracellular disturbance in hCS synthesis in placentas from fetal growth--retarded pregnancies.
D005260:Female; D005317:Fetal Growth Retardation / Q000378:metabolism*; D006801:Humans; D010920:Placenta / Q000032:analysis*; D010928:Placental Lactogen / Q000096:biosynthesis*; D011247:Pregnancy; D012333:RNA, Messenger / Q000378:metabolism*
D012333:RNA, Messenger; D010928:Placental Lactogen